Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study
<p style="text-align:justify;"> <b>Background:</b> Depression is a common psychiatric disorder characterized by a high rate of relapse and recurrence. The most commonly used strategy to prevent relapse/recurrence is maintenance treatment with antidepressant medication (m...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BioMed Central
2012
|
| _version_ | 1797105674840178688 |
|---|---|
| author | Huijbers, M Spijker, J Donders, A Van Schaik, D Van Oppen, P Ruhé, H Blom, M Nolen, W Ormel, J Van Der Wilt, G Kuyken, W Spinhoven, P Speckens, A |
| author_facet | Huijbers, M Spijker, J Donders, A Van Schaik, D Van Oppen, P Ruhé, H Blom, M Nolen, W Ormel, J Van Der Wilt, G Kuyken, W Spinhoven, P Speckens, A |
| author_sort | Huijbers, M |
| collection | OXFORD |
| description | <p style="text-align:justify;"> <b>Background:</b> Depression is a common psychiatric disorder characterized by a high rate of relapse and recurrence. The most commonly used strategy to prevent relapse/recurrence is maintenance treatment with antidepressant medication (mADM). Recently, it has been shown that Mindfulness-Based Cognitive Therapy (MBCT) is at least as effective as mADM in reducing the relapse/recurrence risk. However, it is not yet known whether combination treatment of MBCT and mADM is more effective than either of these treatments alone. Given the fact that most patients have a preference for either mADM or for MBCT, the aim of the present study is to answer the following questions. First, what is the effectiveness of MBCT in addition to mADM? Second, how large is the risk of relapse/recurrence in patients withdrawing from mADM after participating in MBCT, compared to those who continue to use mADM after MBCT?<br/><br/> <b>Methods/design:</b> Two parallel-group, multi-center randomized controlled trials are conducted. Adult patients with a history of depression (3 or more episodes), currently either in full or partial remission and currently treated with mADM (6 months or longer) are recruited. In the first trial, we compare mADM on its own with mADM plus MBCT. In the second trial, we compare MBCT on its own, including tapering of mADM, with mADM plus MBCT. Follow-up assessments are administered at 3-month intervals for 15 months. Primary outcome is relapse/recurrence. Secondary outcomes are time to, duration and severity of relapse/recurrence, quality of life, personality, several process variables, and incremental cost-effectiveness ratio.<br/><br/> <b>Discussion:</b> Taking into account patient preferences, this study will provide information about a) the clinical and cost-effectiveness of mADM only compared with mADM plus MBCT, in patients with a preference for mADM, and b) the clinical and cost-effectiveness of withdrawing from mADM after MBCT, compared with mADM plus MBCT, in patients with a preference for MBCT.<br/><br/> <b>Trial registration:</b> ClinicalTrials.gov: NCT00928980 </p> |
| first_indexed | 2024-03-07T06:50:42Z |
| format | Journal article |
| id | oxford-uuid:fc76bc53-054b-4924-ad9a-5ee5aa01446c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:50:42Z |
| publishDate | 2012 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:fc76bc53-054b-4924-ad9a-5ee5aa01446c2022-03-27T13:20:59ZPreventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fc76bc53-054b-4924-ad9a-5ee5aa01446cEnglishSymplectic Elements at OxfordBioMed Central2012Huijbers, MSpijker, JDonders, AVan Schaik, DVan Oppen, PRuhé, HBlom, MNolen, WOrmel, JVan Der Wilt, GKuyken, WSpinhoven, PSpeckens, A <p style="text-align:justify;"> <b>Background:</b> Depression is a common psychiatric disorder characterized by a high rate of relapse and recurrence. The most commonly used strategy to prevent relapse/recurrence is maintenance treatment with antidepressant medication (mADM). Recently, it has been shown that Mindfulness-Based Cognitive Therapy (MBCT) is at least as effective as mADM in reducing the relapse/recurrence risk. However, it is not yet known whether combination treatment of MBCT and mADM is more effective than either of these treatments alone. Given the fact that most patients have a preference for either mADM or for MBCT, the aim of the present study is to answer the following questions. First, what is the effectiveness of MBCT in addition to mADM? Second, how large is the risk of relapse/recurrence in patients withdrawing from mADM after participating in MBCT, compared to those who continue to use mADM after MBCT?<br/><br/> <b>Methods/design:</b> Two parallel-group, multi-center randomized controlled trials are conducted. Adult patients with a history of depression (3 or more episodes), currently either in full or partial remission and currently treated with mADM (6 months or longer) are recruited. In the first trial, we compare mADM on its own with mADM plus MBCT. In the second trial, we compare MBCT on its own, including tapering of mADM, with mADM plus MBCT. Follow-up assessments are administered at 3-month intervals for 15 months. Primary outcome is relapse/recurrence. Secondary outcomes are time to, duration and severity of relapse/recurrence, quality of life, personality, several process variables, and incremental cost-effectiveness ratio.<br/><br/> <b>Discussion:</b> Taking into account patient preferences, this study will provide information about a) the clinical and cost-effectiveness of mADM only compared with mADM plus MBCT, in patients with a preference for mADM, and b) the clinical and cost-effectiveness of withdrawing from mADM after MBCT, compared with mADM plus MBCT, in patients with a preference for MBCT.<br/><br/> <b>Trial registration:</b> ClinicalTrials.gov: NCT00928980 </p> |
| spellingShingle | Huijbers, M Spijker, J Donders, A Van Schaik, D Van Oppen, P Ruhé, H Blom, M Nolen, W Ormel, J Van Der Wilt, G Kuyken, W Spinhoven, P Speckens, A Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study |
| title | Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study |
| title_full | Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study |
| title_fullStr | Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study |
| title_full_unstemmed | Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study |
| title_short | Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study |
| title_sort | preventing relapse in recurrent depression using mindfulness based cognitive therapy antidepressant medication or the combination trial design and protocol of the moment study |
| work_keys_str_mv | AT huijbersm preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT spijkerj preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT dondersa preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT vanschaikd preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT vanoppenp preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT ruheh preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT blomm preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT nolenw preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT ormelj preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT vanderwiltg preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT kuykenw preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT spinhovenp preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy AT speckensa preventingrelapseinrecurrentdepressionusingmindfulnessbasedcognitivetherapyantidepressantmedicationorthecombinationtrialdesignandprotocolofthemomentstudy |